Demand for weight-loss drugs spurs Novo Nordisk to invest €2.1bn in French production site

Neil Gerrard Senior Editor, Construction Briefing

24 November 2023

Image of the Novo Nordisk logo on a corporate building Image: JHVEPhoto via AdobeStock - stock.adobe.com

Danish drug company Novo Nordisk is to invest 16 billion Danish kroner (€2.1 billion) to expand its production facilities in Chartres, France amid high demand for its weight-loss drugs Ozempic and Wegovy.

The investment involves significantly increasing the capacity of its manufacturing site and extending its current quality control laboratory.

The new multi-product facilities will more than double the footprint of the site.

Construction work is expected to employ around 2,000 people and will gradually be finalised from 2026 to 2028.

Henrik Wulff, executive vice president, product supply, quality & IT at Novo Nordisk said, “Our continued investments in our manufacturing sites across the globe demonstrate the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases.”

Denmark France Construction Industrial
STAY CONNECTED



Receive the information you need when you need it through our world-leading magazines, newsletters and daily briefings.

Sign up

CONNECT WITH THE TEAM
Andy Brown Editor, Editorial, UK - Wadhurst Tel: +44 (0) 1892 786224 E-mail: [email protected]
Neil Gerrard Senior Editor, Editorial, UK - Wadhurst Tel: +44 (0) 7355 092 771 E-mail: [email protected]
Catrin Jones Deputy Editor, Editorial, UK – Wadhurst Tel: +44 (0) 791 2298 133 E-mail: [email protected]
Eleanor Shefford Brand Manager Tel: +44 (0) 1892 786 236 E-mail: [email protected]
CONNECT WITH SOCIAL MEDIA